Stock WXXWY WUXI BIOLOGICS (CAYMAN) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials WuXi Biologics (Cayman) Inc. OTC Markets

Equities

WXXWY

US98260N1081

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 12:01:45 30/05/2024 am IST 		5-day change 1st Jan Change
2.875 USD -2.41% Intraday chart for WuXi Biologics (Cayman) Inc. -13.19% -61.41%
27/05 China stocks rise as industrial profits grow; energy, semiconductor shares lead gains RE
17/05 Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,14,126 3,53,422 3,18,544 2,23,341 1,13,607 44,039 - -
Enterprise Value (EV) 1 1,09,822 3,48,931 3,12,303 2,19,728 1,08,159 36,788 35,849 33,113
P/E ratio 116 x 216 x 97.9 x 52.3 x 34.9 x 11.8 x 9.28 x 8.28 x
Yield - - - - - - - -
Capitalization / Revenue 28.6 x 63 x 31 x 14.6 x 6.67 x 2.43 x 2.04 x 1.82 x
EV / Revenue 27.6 x 62.2 x 30.4 x 14.4 x 6.35 x 2.03 x 1.66 x 1.37 x
EV / EBITDA 65.7 x 142 x 68 x 32 x 15.5 x 5.74 x 4.64 x 3.88 x
EV / FCF -54.8 x -83.5 x -101 x -673 x - 94 x 13.8 x 16.2 x
FCF Yield -1.82% -1.2% -0.99% -0.15% - 1.06% 7.26% 6.18%
Price to Book 8.93 x 17.2 x 10.3 x 6.37 x 2.9 x 0.99 x 0.88 x 0.8 x
Nbr of stocks (in thousands) 38,83,578 40,84,763 42,24,123 42,25,262 42,22,732 41,57,156 - -
Reference price 2 29.39 86.52 75.41 52.86 26.90 10.59 10.59 10.59
Announcement Date 26/03/20 23/03/21 22/03/22 22/03/23 26/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,984 5,612 10,290 15,269 17,034 18,137 21,589 24,249
EBITDA 1 1,671 2,464 4,590 6,857 6,993 6,404 7,723 8,527
EBIT 1 1,156 2,008 3,327 4,609 4,253 4,818 5,984 6,856
Operating Margin 29.02% 35.79% 32.33% 30.18% 24.97% 26.56% 27.72% 28.27%
Earnings before Tax (EBT) 1 1,127 1,966 3,993 5,358 4,174 4,667 5,880 6,623
Net income 1 1,010 1,689 3,388 4,420 3,400 3,852 4,867 5,478
Net margin 25.36% 30.09% 32.93% 28.95% 19.96% 21.24% 22.54% 22.59%
EPS 2 0.2533 0.4000 0.7700 1.010 0.7700 0.8941 1.141 1.279
Free Cash Flow 1 -2,003 -4,178 -3,106 -326.7 - 391.4 2,604 2,046
FCF margin -50.27% -74.44% -30.19% -2.14% - 2.16% 12.06% 8.44%
FCF Conversion (EBITDA) - - - - - 6.11% 33.72% 23.99%
FCF Conversion (Net income) - - - - - 10.16% 53.51% 37.35%
Dividend per Share 2 - - - - - - - -
Announcement Date 26/03/20 23/03/21 22/03/22 22/03/23 26/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 1,944 3,668 4,407 5,883 7,206 8,062 8,492 8,542 7,852 9,835
EBITDA - - - - - - - - - -
EBIT 1 - - 1,773 1,553 2,484 2,054 2,434 1,819 2,033 2,445
Operating Margin - - 40.24% 26.4% 34.47% 25.47% 28.66% 21.29% 25.9% 24.86%
Earnings before Tax (EBT) - 1,261 - - - 2,428 2,529 1,645 - -
Net income - 952.8 - 1,546 - 1,885 2,267 1,133 - -
Net margin - 25.97% - 26.28% - 23.38% 26.69% 13.26% - -
EPS - - - - - - 0.5200 - - -
Dividend per Share - - - - - - - - - -
Announcement Date 21/09/20 23/03/21 23/08/21 22/03/22 17/08/22 22/03/23 23/08/23 26/03/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 4,304 4,491 6,241 3,612 5,448 7,250 8,189 10,926
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -2,003 -4,178 -3,106 -327 - 391 2,604 2,046
ROE (net income / shareholders' equity) 11.6% 10.1% 12.8% 13.1% 9.02% 8.98% 10.1% 10.2%
ROA (Net income/ Total Assets) 8.93% 7.25% 9.28% 9.45% 6.41% 6.8% 7.86% 8.07%
Assets 1 11,317 23,283 36,498 46,798 53,070 56,649 61,944 67,864
Book Value Per Share 2 3.290 5.030 7.300 8.290 9.270 10.70 12.10 13.30
Cash Flow per Share 2 0.3000 0.4400 0.7700 1.270 - 1.580 1.760 1.830
Capex 1 3,211 6,025 6,508 5,868 - 5,229 4,555 3,936
Capex / Sales 80.59% 107.35% 63.24% 38.43% - 28.83% 21.1% 16.23%
Announcement Date 26/03/20 23/03/21 22/03/22 22/03/23 26/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
10.6 CNY
Average target price
24.91 CNY
Spread / Average Target
+135.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.46% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+9.34% 10TCr
BIONTECH SE Stock BioNTech SE
-12.20% 2.27TCr
ARGENX SE Stock argenx SE
+2.21% 2.18TCr
GENMAB A/S Stock Genmab A/S
-10.88% 1.82TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.90% 1.65TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.69% 1.6TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.75% 1.41TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.99% 1.07TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2269 Stock
  4. WXXWY Stock
  5. Financials WuXi Biologics (Cayman) Inc.